Overview

Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effectiveness of desloratadine at doses higher (10 mg and 20 mg) than currently approved (5 mg) for the treatment of chronic idiopathic urticaria. Subjects with chronic urticaria who are currently taking a second generation antihistamine will be treated with desloratadine (5, 10, or 20 mg) for 28 days.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Desloratadine
Loratadine